Table 4.
Correlation of MPO concentration and activity in the CSF with demographic and clinical parameters in male and female patients with idiopathic Parkinson’s disease.
| MPO Content | MPO Activity | |||
|---|---|---|---|---|
| Parameter | Men (n = 18) | Women (n = 16) |
Men (n = 18) |
Women (n = 16) |
| Age, years | 0.158 | 0.405 | −0.022 | −0.023 |
| Body mass index | 0.101 | 0.087 | −0.024 | −0.025 |
| Education, years | 0.275 | −0.364 | 0.159 | −0.306 |
| Albumin index | 0.021 | 0.028 | −0.149 | −0.103 |
| Leukocyte count, cells/µL | 0.101 | 0.204 | 0.212 | 0.186 |
| CSF MPO activity | 0.470 * | 0.498 * | ||
| Serum MPO content | −0.387 | 0.216 | −0.174 | −0.109 |
| Serum MPO activity | 0.128 | 0.326 | 0.314 | −0.273 |
| Levodopa equivalent daily dose, mg | 0.016 | 0.076 | 0.230 | 0.331 |
| Disease duration, years | 0.469 * | 0.565 * | 0.404 | −0.276 |
| Age-at-PD onset, years | −0.135 | −0.024 | −0.256 | 0.329 |
| Hoehn–Yahr stage | −0.048 | −0.236 | 0.343 | 0.104 |
| Modified Schwab–England | −0.018 | −0.401 | 0.010 | −0.006 |
| MDS-UPDRS part III (on) | −0.019 | −0.307 | 0.324 | 0.013 |
| Total MDS-UPDRS (I-III) (on) | −0.017 | −0.183 | 0.292 | −0.120 |
| MDS-UPDRS part IV (all patients) | 0.216 | −0.012 | 0.320 | −0.080 |
Statistical correlation was carried out with the Pearson’s test. Correlation value was adjusted for age, age-at-PD onset, body mass index, and education. * p< 0.05. Abbrev.: AOPP, advanced oxidation protein products; CSF, cerebrospinal fluid; MPO, myeloperoxidase; NS, no significant; MDS-UPDRS, International Parkinson and Movement Disorder Society-Sponsored revision of the Unified Parkinson’s Disease Rating Scale; PD, Parkinson’s disease.